Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Amicus Therapeutics (FOLD) over the last 16 years, with Q3 2025 value amounting to -$7.6 million.

  • Amicus Therapeutics' Other Working Capital Changes rose 4690.33% to -$7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 13258.38%. This contributed to the annual value of -$14.0 million for FY2024, which is 27317.04% down from last year.
  • As of Q3 2025, Amicus Therapeutics' Other Working Capital Changes stood at -$7.6 million, which was up 4690.33% from $4.8 million recorded in Q2 2025.
  • Amicus Therapeutics' 5-year Other Working Capital Changes high stood at $15.0 million for Q4 2021, and its period low was -$19.3 million during Q2 2024.
  • Moreover, its 5-year median value for Other Working Capital Changes was $1.1 million (2022), whereas its average is $368473.7.
  • The largest annual percentage gain for Amicus Therapeutics' Other Working Capital Changes in the last 5 years was 114745.92% (2023), contrasted with its biggest fall of 303747.95% (2023).
  • Amicus Therapeutics' Other Working Capital Changes (Quarter) stood at $15.0 million in 2021, then crashed by 95.93% to $611000.0 in 2022, then plummeted by 3037.48% to -$17.9 million in 2023, then skyrocketed by 179.42% to $14.3 million in 2024, then crashed by 153.1% to -$7.6 million in 2025.
  • Its Other Working Capital Changes was -$7.6 million in Q3 2025, compared to $4.8 million in Q2 2025 and $3.6 million in Q1 2025.